EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Efficacy and safety of finerenone in chronic kidney disease stages 3–4 in diabetic and non-diabetic patients with an eGFR 20–60 mL/min: a prospective cohort study

Hayder Aledan, Ammar Salih Abbood

Frontiers in Nephrology · 08.05.2026 · 6

DOI: 10.3389/fneph.2026.1716452 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Nephrology, online erschienen am 08.05.2026. Verfasst von Hayder Aledan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, College of Medicine, Medicine, University of Basrah, Basrah, Iraq. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Finerenone, when added to the standard-of-care treatment for chronic kidney disease (CKD), can effectively slow its progression. While previous trials have primarily focused on patients with diabetic kidney disease and an estimated glomerular filtration rate (eGFR) above 25 ml/min, this study aimed to evaluate the efficacy and safety of finerenone in patients with CKD stage 3–4, encompassing both diabetic and non-diabetic patients with an eGFR ranging from 20 to 60 ml/min.

Methods

This prospective cohort study included 180 patients with CKD stage 3–4, including diabetic and non-diabetic participants. These patients had an eGFR of 20–60 ml/min and an urinary albumin-to-creatinine ratio (UACR) higher than 30 mg/g. The study was conducted between January 2023 and June 2024 at the Basra Nephrology and Transplantation Center and Private Clinic.

Results

Finerenone showed statistically significant improvements in eGFR and UACR over a one-year period among all patient groups, including the subgroup of non-diabetic patients and patients with an eGFR between 20 and 25 ml/min (P < 0.001). Importantly, finerenone did not elevate serum potassium levels. The study population had a mean age of 61.67 ± 13.37 years, 50.6% aweremen,78% awerewdiabetic,22% awerewnon-diabeticand 65 (36%) hhadFR of 20–25 ml/min.

Conclusions

Finerenone is a safe and effective approach for slowing the progression of CKD in patients with an eGFR > 20 ml/min and moderately to severely increased albuminuria, regardless of diabetes status.

Schlagwörter

Stichwörter der Autor:innen

EGFRGLP1-raSGLT2IUACRfinerenone

Autor:innen und Institutionen

  • Nephrology, College of Medicine, Medicine, University of Basrah, Basrah, Iraq.
  • Cardiology, College of Medicine, Medicine, University of Basrah, Basrah, Iraq.

Zitieren

APA

Aledan, H., & Abbood, A. S. (2026). Efficacy and safety of finerenone in chronic kidney disease stages 3–4 in diabetic and non-diabetic patients with an eGFR 20–60 mL/min: a prospective cohort study. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1716452

Vancouver

Aledan H, Abbood AS. Efficacy and safety of finerenone in chronic kidney disease stages 3–4 in diabetic and non-diabetic patients with an eGFR 20–60 mL/min: a prospective cohort study. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1716452

BibTeX
@article{Aledan2026,
  author = {Aledan, Hayder and Abbood, Ammar Salih},
  title = {Efficacy and safety of finerenone in chronic kidney disease stages 3–4 in diabetic and non-diabetic patients with an eGFR 20–60 mL/min: a prospective cohort study},
  journal = {Frontiers in Nephrology},
  year = {2026},
  volume = {6},
  doi = {10.3389/fneph.2026.1716452}
}
Kostenlos starten →